엘앤케이바이오

156100KOSDAQ의료용 기기 제조업

39.6 / 100

Reference Date: 2026-06-10

Financial Score8.5 / 40

News Sentiment19.1 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Plunged 23.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Elan K Bio is a specialized medical device company focusing on the design, development, manufacturing, and sales of spinal implants used in orthopedic and neurosurgical procedures. Its products, classified as Class 3 medical devices, account for 95.9% of revenue generated primarily in the Americas.

Number of Employees

97people

Average Salary

60.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 21.514.0Point

PBR

2.88Industry Average 1.380.0Point

2.1x industry avg (risky)

ROE

-44.98Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

16.87Industry Average 11.652.0Point

Higher than industry avg (caution)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲14.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼12.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -14.3% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 1Negative 0Average Sentiment Score 76.2

Positive
엘앤케이바이오, 태국서 '팩투스' 라이브 서저리 워크숍 실시
엘앤케이바이오의 태국 의료진 대상 라이브 서저리 워크숍 성공적 개최로 글로벌 시장 확장 기대감 증가.
Neutral
메디컬아이피, 신임 사외이사로 전문경영인 출신 박근주 선임
메디컬아이피의 신임 사외이사 선임 소식은 회사의 경영 전문성 강화에 기여할 것으로 보이나, 엘앤케이바이오와 직접적인 연관성이 적어 영향은 제한적이다.
Positive
엘앤케이바이오, 경추용 높이확장형 케이지 'BluEX-C' FDA 승인
엘앤케이바이오의 새로운 경추용 높이확장형 케이지 'BluEX-C'의 FDA 승인으로 기술 경쟁력이 입증되어 시장 확대 기대감이 높아짐.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 4,970Won52-week high 15,89052-week low 4,970

1-month return0.0Point

1m -23.77% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15